TerThera b.v.

Today the conference #ALASBIMN took off in Cancún, Mexico. Join the conversation at booth #50 with Philippe van Overeem and Stuart Chalk on the impact of Terbium-161 within the field of Nuclear Medicine. #LATAM #Tb161 #Terbium161

Today, we performed our first-ever PSMA-targeting radioligand therapy with Terbium-161 (¹⁶¹Tb-PSMA). It’s likely to be the very first one in the whole of Europe in outpatient mode.   With its unique radiation profile, ¹⁶¹Tb offers new hope for those who have exhausted all other treatment options. Stay tuned for the results.   This marks a major milestone in bringing next-generation targeted therapy to patients with metastatic prostate cancer. We extend our gratitude to medisynt & TerThera b.v. for providing the high-quality Terbium-161, making this groundbreaking therapy possible!

Congratulations on another monumental achievement for Lagos Nuclear Medicine Department LMC! It is truly remarkable to be the first center in Nigeria, and the second country in Africa, to administer and offer the groundbreaking Terbium-161 cancer treatment. This cutting-edge therapy, with its unique beta-decay (6.95 days) and production process, not only provides gamma emissions for post-therapy SPECT imaging but also enhances treatment with additional auger emissions. The ability to target micrometastatic disease, delivering approximately 3.5 times the radiation dosage to the cells while ensuring that smaller cells receive radiation equivalent to larger ones, marking a significant advantage in cancer treatment. Thank you, TerThera b.v. for your unwavering support, outstanding production, and remarkable efforts in ensuring timely delivery. Your dedication is greatly appreciated! I am deeply grateful for this extraordinary blessing and for the Lord’s guiding hand in making these advancements possible. TerThera b.v. Loveworld Medical Centre Umhlanga Molecular Imaging and Therapy Masha Maharaj Samantha Du Plessis Trisha Govender Oluwapelumi Adekola Olapade Dolapo Oreoluwa Olasoju Desmond Mamah Anjolaoluwa Akinyemi #Terbium-161 #Cancer #Theragnostics #Treatment #Radionuclidetherapy #NuclearMedicine

Milestone reached. With the extended geographical reach, we were able to meet the demand for Terbium-161 (Tb-161) on 6 continents by ramping up the production that has led to reaching the threshold 200Ci or 7.4TBq Terbium-161 produced and expedited. #Terbium161 #Tb161 #161Tb

Please give a warm welcome to our newest member of the TerThera b.v. team, Imke Boekestijn! Imke will have an instrumental role as Quality and Validation Engineer to further strengthen the #Terbium161 platform, safeguarding the highest level of quality and preparing our processes for the next scale-up phase. “Amazing to join TerThera in such a significant role and to experience the impact of a novel and groundbreaking radionuclide, both from an academic and industrial perspective,” said Imke Boekestijn, Quality and Validation Engineer at TerThera.

Grab your agenda! During the first half of 2025 TerThera b.v. will be present at various events within the field of Nuclear Medicine. Visit us at any of the following events to discuss your supply of #Terbium161 and how we can support your initiatives! Asociación Latinoamericana de Sociedades de Biología y Medicina Nuclear (ALASBIMN) in Benito Juárez, Quintana Roo, Mexico, March 13-16, 2025.   63rd Annual Conference of the DGN Deutsche Gesellschaft für Nuklearmedizin e. V. in Bremen, Germany, April 2-5, 2025   International Conference on Nuclear Medicine and Medical Applications  (#ICNMMA) in Dubai, April 19, 2025 International Symposium on Radiopharmaceutical Sciences (#iSRS) Gold Coast in Queensland, Australia, May 11-15, 2025   Belgian Association of Nuclear Medicine (BELNUC Association) in Brugge, Belgium, May 16-18, 2025   Australian and New Zealand Society of Nuclear Medicine (#ANZSNM) in Melbourne, Australia, May 23-25, 2025 Annual conference Society of Nuclear Medicine and Molecular Imaging (SNMMI) in New Orleans, USA, June 21-25, 2025

A novel application of #Terbium161 has been published. A form of injectable nanobrachytherapy using radiolabeled nanaparticles 161Tb-nf Au@TADOTAGA proved to be stable carriers of the Auger-emitting radioisotope #161Tb displaying significant retention time. With the opportunity for imaging, using MRI or CT modalities, this #Tb161 nanobrachytherapy agent may open doors to localized treatment of cancer. Our compliments to the research consortium for this amazing work! Université de Franche-Comté Université de Bourgogne NCSR "DEMOKRITOS"

It’s, “ALL OF US, TOGETHER”, believing in the Ideology, “Patients First”, Serving Humanity, THERANOSTICS, Is The Way forward. #NuclearMedicine #PrecisionOncology #Theranostics #SNMICON2024 #ABX #ITM #TerThera #RadiomolecularPrecisionOncology #Cancer #Cancercare #Oncology #NuclearMedicine #Treatment #Cancertreatment #aAphaemitters #Radiopharmaceuticals #FAP #Radiopharmaceuticalstherapy #Therapy #Clinicaltrials #RLT #Ligands #Diagnostics #Alphatherapy

🌟 A Step Forward in Prostate Cancer Treatment 🌟We are excited to share that we have successfully applied Terbium-161 PSMA therapy in our second clinical case, as part of the clinical trial conducted across 7 centers in Turkey.This promising therapy offers new hope to patients battling metastatic prostate cancer and represents a meaningful advancement in targeted radionuclide treatment.A heartfelt thank you to TerThera b.v. and EDH Nükleer Tıp ve Sağlık Hizmetleri for their unwavering support and collaboration in making this treatment possible. Together, we’re striving to make a real difference in patients’ lives.We’ll continue to share updates as we move forward in our work to advance nuclear medicine and improve outcomes for those who need it most.#ProstateCancer #RadionuclideTherapy #Terbium161 #PSMA #NuclearMedicine F. Gül Gümüşer Yasemin Parlak

A promising step in the field of nuclear medicine: At the symposium organized by the Turkish Society of Nuclear Medicine, the first results of the multi center study conducted in Türkiye about Tb-161 treatment were presented. Prof. Dr. Nuriye Ozlem Kucuk from the Department of Nuclear Medicine at Ankara University Cebeci Hospital shared data from a study of a 58-year-old prostate cancer patient. This study includes observations of developments in the treatment process and changes in PSA levels. These findings represent an important starting point for Tb-161 research in Türkiye. Initial results from multicenters indicate promising progress. We will continue to support innovative solutions in healthcare and develop patient-centered treatments. You can access the post-treatment whole-body imaging in the PDF: https://lnkd.in/dpv3n9YS TerThera b.v. #AnkaraÜniversitesiCebeciTıpFakültesi #ManisaCelalBayarÜniversitesiHafsaSultanHastanesi #İstanbulÜniversitesiİstanbulTıpFakültesi #AnkaraBilkentŞehirHastanesi #AnadoluSağlıkMerkezi #YeditepeÜniversitesiHastaneleri #MedicalParkHastanelerGrubu #edhnuclear #prostatecancer #tb161